Potential of the Introduction of Tedizolid for the Treatment of Complicated Skin and Soft Tissue Infections in a Russian Multi-Field Hospital | CMAC

Potential of the Introduction of Tedizolid for the Treatment of Complicated Skin and Soft Tissue Infections in a Russian Multi-Field Hospital

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(3):174-185

​ Belkova Yu.А., Rachina S.A., Kozlov R.S., Golub A.V., Portnyagina U.S., Shamaev S.H.
complicated skin and soft tissue infection cSSTI tedizolid methicillin-resistant Staphylococcus aureus MRSA Budget Impact Analysis
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(3):174-185

Abstract

Increase in prevalence of methicillin-resistant Staphylococcus aureus (MRSA) strains among the pathogens of complicated skin and soft tissue infections (cSSTIs) in hospitalised patients demands introduction of new treatment options with improved efficacy and safety into clinical practice such as novel oxazolidinone antibiotic — tedizolid. We aimed to assess impact of introduction of tedizolid for the treatment of hospitalized patients with cSSTIs presumptively сaused by MRSA on the budget of a Russian multi-field hospital. The budget for the treatment of presumptive MRSA cSSTIs in a hypothetic cohort of 100 hospitalised patients with the current mix of treatment options amounts to 4,865,665 RUB. Replacement of 25% of linezolid by tedizolid leads to total budget decrease of 105,656 RUB, 50% — of 212,374 RUB, 100% — of 428,996 RUB and hospital bed usage optimisation by 1.9%, 3.9% and 8.1% respectively.

Yuliya А. Belkova

Smolensk State Medical University, Smolensk, Russia

Svetlana A. Rachina

RUDN University, Moscow, Russia

Roman S. Kozlov

Smolensk State Medical University, Smolensk, Russia

Alexey V. Golub

Smolensk State Medical University, Smolensk, Russia

Portnyagina U.S.

Republic Hospital #2 — Centre for Emergency Medicine, Yakutsk, Russia

Shamaev S.H.

Republic Hospital #2 — Centre for Emergency Medicine, Yakutsk, Russia

  • 1. Хирургические инфекции кожи и мягких тканей. Российские национальные рекомендации. Под ред. В.С. Савельева. Москва, 2009 г.
  • 2. Zervos M.J., Freeman K., Vo L., et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012; 50: 238-45.
  • 3. Labreche M.J., Lee G.C., Attridge R.T., et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2013; 26: 508- 17.
  • 4. Сухорукова М.В., Склеенова Е.Ю., Иванчик Н.В. и соавт. Антибиотико-резистентность нозокомиальных штаммов Staphylococcus aureus в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011- 2012 гг. Клин микробиол антимикроб химиотер 2014; 16(4):280-6.
  • 5. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-40
  • 6. Zhanel G.G., Love R., Adam H., et al. Tedizolid: A Novel oxazolidinone with potent activity against multidrugresistant gram-positive pathogens. Drugs 2015; 75(3): 253-70.
  • 7. Moran G.J., Fang E., Corey G.R., et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial Lancet Infect Dis. 2014;14:696-705.
  • 8. Prokocimer P., De Anda C., Fang E., et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013; 309: 559-6
  • 9. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of HealthSystem Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.
  • 10. Тарифное соглашение на оплату медицинской помощи, оказываемой по территориальной программе обязательного медицинского страхования города Москвы на 2016 год от 25.12.2015. http://www.mgfoms.ru/ medicinskie-organizacii/tarifi
  • 11. Отчет о работе отделения гнойной хирургии ОГБУЗ «Смоленская областная клиническая больница» за 2015 г.
  • 12. Kuo D.C., Chasm R.M., Witting M.D. Emergency physician ability to predict methicillin-resistant Staphylococcus aureus skin and soft tissue infections. J Emerg Med 2010;39(1):17-20.
  • 13. McCool R., Eales J., Barata T., et al. Systematic Review and Network Meta-analysis of Tedizolid for the Treatment of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) due to Methicillin-Resistant Staphylococcus aureus (MRSA). 20th ISPOR 2015, PIN 17.
  • 14. Yue J., Dong B.R., Yang M., Chen X., Wu T., Liu G.J. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013; 7:CD008056.
  • 15. Polyzos K.A., Mavros M.N., Vardakas K.Z., et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 2012;7(8): e41870.
  • 16. Bally M., Dendukuri N., Sinclair A., Ahern S.P., Poisson M., Brophy J. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents 2012;40(6):479-95.
  • 17. Medic G., Karabis A., Borrill J., Worrall J., Bergman G. Efficacy of ceftaroline fosamil and other intravenous antibiotics in the treatment of complicated skin and soft tissue infections (CSSTI): a network meta-analysis (NMA). ISPOR 15th Annual European Congress, Berlin, 2012. PIN7.
  • 18. Logman J.F., Stephens J., Heeg B., et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 2010;26(7):1565-78.
  • 19. Bounthavong M., Hsu D.I. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA)complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 2010;26(2):407-21.
  • 20. Bliziotis I.A., Plessa E., Peppas G., Falagas M.E. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a metaanalysis. Ann Pharmacother 2010;44(1):97-106.
  • 21. Beibei L., Yun C., Mengli C., Nan B., Xuhong Y., Rui W. Linezolid versus vancomycin for the treatment of grampositive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010;35(1):3- 12.
  • 22. Cadena J., Nair S., Henao-Martinez A.F., et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011;55(12):5430-2.
  • 23. Talbot G.H., Thye D., Das A., et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-6.
  • 24. Lin D.F., Zhang Y.Y., Wu J.F., et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 2008;32(3):241-9.
  • 25. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin Infect Dis 2002;34(11):1481-90.
  • 26. Kohno S., Yamaguchi K., Aikawa N., et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;60(6):1361-9.
  • 27. Weigelt J., Itani K., Stevens D., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49(6):2260-6.
  • 28. Wilcox M.H., Tack K.J., Bouza E., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48(2):203-12.
  • 29. Stryjewski M.E., Graham D.R., Wilson S.E., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structureinfections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93.
  • 30. Florescu I., Beuran M., Dimov R., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62 Suppl 1: i17-28.
  • 31. China Registration Study in Patients With Skin Infections. https://clinicaltrials.gov/ct2/show/study/NCT00772447?term=daptomycin&rank=59
  • 32. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81.
  • 33. Miller L.G., Daum R.S., Creech C.B., et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015;372(12):1093-103.
  • 34. Rybak M.J., Albrecht L.M., Boike S.C., et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25(4):679-87.
  • 35. van Hal S.J., Paterson D.L., Lodise T.P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57(2):734-44.
  • 36. Comparison of telavancin and vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant Staphylococcus aureus (ATLAS1). https://clinicaltrials.gov/ct2/show/NCT00091819?term=ATLAS+telavancin&rank=1
  • 37. Comparison of telavancin and vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant Staphylococcus aureus (ATLAS2). https://clinicaltrials.gov/ct2/show/NCT00107978?term=ATLAS+telavancin&rank=2
  • 38. Schöpf E. Skin reactions to co-trimoxazole. Infection 1987;15 Suppl 5: S254-8.
  • 39. Портал ФАРМ-индекс. http://www.pharmindex.ru
  • 40. Государственный реестр предельных отпускных цен. http://grls.rosminzdrav.ru/pricelims.asp
Views
0 Abstract
0 PDF
0 Crossref citations
Shared